Related Experiment Video
Updated: May 19, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
HIV integrase inhibitors in ART-experienced patients
Jose-Luis Blanco1, Javier Martinez-Picado
1Division of Infectious Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain. jlblanco@clinic.ub.es
Purpose Of Review:
We review the most recent clinical trials of integrase inhibitors (INIs) in antiretroviral therapy (ART)-experienced patients, including trails of new strategies such as intensification and simplification therapy with this new class of compounds.
Recent Findings:
After the excellent results of the first-generation INIs [raltegravir (RAL) and elvitegravir] in the treatment of ART-experienced patients, dolutegravir--a new second-generation compound in this drug class--adds the possibility of rescuing ART-experienced patients after virologic failure to first-generation INIs like RAL. RAL may have a role in an intensification strategy--adding RAL to a suppressive ART therapy--that could have an effect in avoiding new cycles of infection and cellular activation. On the contrary, RAL has clearly shown efficacy in switching away from boosted protease inhibitors (PI/r). This simplification strategy may be an interesting option in patients suffering from side effects of boosted protease inhibitors. In simplification, the length of time of HIV suppression before the switch may be used as a marker of probable success.
Summary:
In ART-experienced patients INIs are a new and exciting part of the armamentarium for the control of HIV replication. INIs could play an interesting role in strategies such as intensification or simplification.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Inhibitors of Viral Protein Synthesis
Retroviruses
Subviral Agents
Size and Structure of Viral Genomes

